NRIX
Nurix Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -12.5% ·
share flow +4.8% ·
net new positions -14.3%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | +2 | 57.55M | $1.40B | +9 | −7 |
| Q1 2026 | 81 | +9 | 58.06M | $899.96M | +14 | −5 |
| Q4 2025 | 72 | -4 | 55.79M | $1.06B | n/a | −4 |
| Q3 2025 | 18 | +1 | 36.35M | $335.90M | +1 | n/a |
| Q2 2025 | 14 | -2 | 38.82M | $442.11M | n/a | −2 |
| Q1 2025 | 13 | 0 | 15.31M | $181.88M | +1 | −1 |
| Q4 2024 | 13 | -1 | 15.53M | $292.61M | +1 | −2 |
| Q3 2024 | 13 | -1 | 13.04M | $292.98M | +1 | −2 |
| Q2 2024 | 14 | n/a | 12.64M | $263.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 10.44M | n/a | $118.94M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 6.81M | n/a | $77.55M | 0.0% | n/c | 1 | SEC ↗ ×14 |
| 3 | The Vanguard Group ✦ (passive) | 4.47M | n/a | $50.86M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 4 | Point72 Asset Management ✦ | 3.70M | +1595.4% | $42.18M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 3.03M | +4.1% | $34.56M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 2.53M | -11.5% | $28.84M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 1.88M | +9.1% | $21.44M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 1.59M | +20.6% | $18.10M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 9 | ARK Investment Management ✦ | 1.58M | -1.0% | $17.94M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.47M | -54.1% | $16.69M | 0.0% | ▼ Trim | 5 | SEC ↗ ×6 |
| 11 | Millennium Management ✦ | 927.56K | +6.1% | $10.56M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 210.00K | -9.5% | $2.39M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 158.72K | -38.4% | $1.81M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 21.90K | -63.2% | $249,441 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| D. E. Shaw & Co. | $711,885 | was 0.0% |
| AQR Capital Management | $138,615 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 116.98M shares, $1.75B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.45K sh · $36,300
Director · 22.58K sh · $528,528
Officer · 1.45K sh · $36,982
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology